NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Lykiri, I am glad that NWBio is not making the same mistake that Iovance and Mesoblast made, that delayed commercial approval of their new BLA and MAA, on the basis that their potency assay for drug product release was inadequate.

As shown by Dr. Bosch and Dr. Murthy, in their presentation at ASCO last year, NWBio, along with Flaskworks and Advent, have been working on developing, and improving quality control assays, product release assays, and potency assays for DCVax-L for years now. As a result, they have refined and perfected these processes

NWBio ASCO 2022